Predictive factors of Clostridioides difficile infection in hospitalized patients with new diarrhea: A retrospective cohort study
- PMID: 30517148
- PMCID: PMC6281280
- DOI: 10.1371/journal.pone.0207128
Predictive factors of Clostridioides difficile infection in hospitalized patients with new diarrhea: A retrospective cohort study
Abstract
Introduction and objective: Diagnostic testing for Clostridioides difficile infection (CDI) by nucleic acid amplification test (NAAT) cannot distinguish between colonization and infection. A positive NAAT may therefore represent a false positive for infection, since diarrhea due to various aetiologies may occur in hospitalized patients. Our objective was to help answer the question: "does this medical inpatient with diarrhea have CDI?"
Design: We conducted a retrospective cohort study (n = 248) on the Clinical Teaching Units of the Royal Victoria Hospital (Montréal, Canada). Patients were included if they had a NAAT between January 2014 and September 2015 and their admission diagnosis was not CDI. CDI cases and non-CDI cases were compared, and independent predictors of CDI were determined by logistic regression.
Results: Several factors were independently associated with CDI, including: hemodialysis (OR: 13.5, 95% CI: 2.85-63.8), atrial fibrillation (OR: 3.70, 95% CI: 1.52-9.01), whether the patient received empiric treatment (OR: 3.01, 95% CI: 1.04-8.68), systemic antibiotic therapy prior to testing (OR: 4.23, 95% CI: 1.71-10.5), previous positive NAAT (OR: 3.70, 95% CI: 1.41-9.72), and a leukocyte count of 11x109/L or higher (OR: 3.43, 95% CI: 1.42-8.26). The area under the curve was 0.80.
Conclusion: For patients presenting with hospital-onset diarrhea, various parameters can help differentiate between CDI and other causes. A clinical prediction calculator derived from our cohort (http://individual.utoronto.ca/leet/cdiff.html) might assist clinicians in estimating the risk of CDI for inpatients; those with low pre-test probability may not require immediate testing, treatment, nor prolonged isolation.
Conflict of interest statement
The authors have declared that no competing interests exist.
Similar articles
-
Analysis of Intestinal Mycobiota of Patients with Clostridioides difficile Infection among a Prospective Inpatient Cohort.Microbiol Spectr. 2022 Aug 31;10(4):e0136222. doi: 10.1128/spectrum.01362-22. Epub 2022 Jul 14. Microbiol Spectr. 2022. PMID: 35867408 Free PMC article.
-
Diagnosis and outcome of Clostridium difficile infection by toxin enzyme immunoassay and polymerase chain reaction in an island population.J Gastroenterol Hepatol. 2017 Feb;32(2):415-419. doi: 10.1111/jgh.13504. J Gastroenterol Hepatol. 2017. PMID: 27505006
-
Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non-C. difficile Diarrhea.Clin Infect Dis. 2020 Mar 3;70(6):1083-1093. doi: 10.1093/cid/ciz330. Clin Infect Dis. 2020. PMID: 31211839 Free PMC article.
-
Optimizing the Laboratory Diagnosis of Clostridium difficile Infection.Clin Lab Med. 2015 Jun;35(2):299-312. doi: 10.1016/j.cll.2015.02.003. Epub 2015 Mar 18. Clin Lab Med. 2015. PMID: 26004644 Review.
-
Current knowledge on the laboratory diagnosis of Clostridium difficile infection.World J Gastroenterol. 2017 Mar 7;23(9):1552-1567. doi: 10.3748/wjg.v23.i9.1552. World J Gastroenterol. 2017. PMID: 28321156 Free PMC article. Review.
Cited by
-
Risk, Outcomes, and Trends of Clostridium Difficile Infection in Multiple Myeloma Patients from a Nationwide Analysis.Cureus. 2019 Apr 5;11(4):e4391. doi: 10.7759/cureus.4391. Cureus. 2019. PMID: 31205828 Free PMC article.
-
Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options.Clin Microbiol Rev. 2024 Jun 13;37(2):e0013523. doi: 10.1128/cmr.00135-23. Epub 2024 Feb 29. Clin Microbiol Rev. 2024. PMID: 38421181 Free PMC article. Review.
-
The Global Burden of Clostridioides difficile Infections, 2016-2024: A Systematic Review and Meta-Analysis.Infect Dis Rep. 2025 Apr 14;17(2):31. doi: 10.3390/idr17020031. Infect Dis Rep. 2025. PMID: 40277958 Free PMC article. Review.
References
-
- M100: Performance Standards for Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute, 2018.
-
- Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile–associated diarrhea with high morbidity and mortality. New England Journal of Medicine. 2005;353(23):2442–9. 10.1056/NEJMoa051639 - DOI - PubMed
-
- Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, et al. A large outbreak of Clostridium difficile–associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infection Control & Hospital Epidemiology. 2005;26(3):273–80. - PubMed
-
- Pépin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile–associated disease during an epidemic caused by a hypervirulent strain in Quebec. Canadian Medical Association Journal. 2005;173(9):1037–42. 10.1503/cmaj.050978 - DOI - PMC - PubMed
-
- Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile–related mortality rates, United States, 1999–2004. Emerging infectious diseases. 2007;13(9):1417 10.3201/eid1309.061116 - DOI - PMC - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical